18631-37-3

Upstream product

• 4604-06-2 2-amino-4,6-diphenylnicotinonitrile 
• 614-47-1 1,3-diphenyl-propen-3-one 
• 94-41-7 benzalacetophenone 

Downstream Products

• 129055-43-2 5,7-Diphenyl-2-thioxo-3-p-tolyl-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-45-4 3-(4-Methoxy-phenyl)-5,7-diphenyl-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-44-3 3-(2-Methoxy-phenyl)-5,7-diphenyl-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-46-5 3-Cyclohexyl-5,7-diphenyl-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-41-0 5,7-Diphenyl-2-thioxo-3-o-tolyl-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-42-1 5,7-Diphenyl-2-thioxo-3-m-tolyl-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-40-9 3-Butyl-5,7-diphenyl-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one 
• 69932-55-4 5,7-diphenyl-2-methyl-3,4-dihydropyrido[2,3-d]pyrimidin-4-one 
• 69932-56-5 5,7-diphenyl-3,4-dihydropyrido[2,3-d]pyrimidin-4-one 
• 1352714-92-1 2,5,7-triphenylpyrido[2,3-d]pyrimidin-4-ol 
• 129055-56-7 2-Morpholin-4-yl-5,7-diphenyl-3-m-tolyl-3H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-57-8 3-Cyclohexyl-2-morpholin-4-yl-5,7-diphenyl-3H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-59-0 5,7-Diphenyl-2-piperidin-1-yl-3-m-tolyl-3H-pyrido[2,3-d]pyrimidin-4-one 
• 129055-60-3 3-Cyclohexyl-5,7-diphenyl-2-piperidin-1-yl-3H-pyrido[2,3-d]pyrimidin-4-one 

Relevant academic research and scientific papers

Synthesis, Anti-Microbial, and Cytotoxic Activities Evaluation of Some New Pyrido[2,3-d]Pyrimidines

Novel pyridine derivatives 1d and 7, pyrido[2,3-d]pyrimidine derivatives 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 4a, 4b, 4c, 4d, 5a, 5b, 5c, 5d, 6a, 6b, 6c, 6d, 8a,8b, and 9a,9b were synthesized and screened for their anti-microbial and cytotoxic activities. Comp

2,6,8, Trisubstituted 1-deazapurines and their different uses

The invention provides a compound having the structure of general formula (I): or a salt thereof, wherein, R represents hydrogen (except when R′=H), halogen, (substituted) alkyl except —CH3, (substituted) alkenyl, (substituted) alkynyl, or (sub

2,6,8-Trisubstituted 1-deazapurines as adenosine receptor antagonists

In this study we developed a refined pharmacophore model for antagonists of the human adenosine A1 receptor, based on features of known pyrimidine and purine derivatives. The adoption of these updated criteria assisted us in synthesizing a series of 1-deazapurines with consistently high affinity as inverse agonists for the adenosine A1 receptor. These 1-deazapurines (otherwise known as 3H-imidazo[4,5-b]pyridines) were substituted at their 2- and 6-positions, yielding a series with five of the derivatives displaying Ki values in the subnanomolar range. The most potent of these, compound 10 (LUF 5978), displayed an affinity of 0.55 nM at the human adenosine A1 receptor with > 300-fold and 45-fold selectivity toward A2A and A3 receptors, respectively. Compound 14 (LUF 5981, Ki = 0.90 nM) appeared to have the best overall selectivity with respect to adenosine A2A (> 200-fold) and A 3 (700-fold) receptors.

Synthesis of nucleosides of 5,7-disubstituted pyrido [2,3-d] pyrimidines and their antibacterial activity

Synthesis of 4-amino-5,7-diphenyl-1-(β-D-ribofuranosyl) pyrido [2,3-d] pyrimidin-2-ones nucleoside, 4-amino-5,7-disubstituted-1-(β-D-ribofuranosyl) pyrido [2,3-d] pyrimidin-2-thiones nucleosides, 2-thioxo-3,5,7-triphenyl-1-(β-D-ribofuranosyl) pyrido [2,3-